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Description

Coronavirus disease 2019 (COVID-19) may result in severe acute respiratory disease syndrome (ARDS) and death. For COVID-19 patients failing mechanical ventilation, extra
corporeal membrane oxygenation (ECMO) has been used with varying efficacy in academic
medical centers and quaternary referral centers. We report the successful use of veno-venous (VV) ECMO to treat refractory ARDS due to COVID-19 in a community hospital setting
with a survival to discharge rate of 71% over a 3 month period. In a community hospital with
adequate resources, VV ECMO can be an effective rescue therapy for selected COVID-19
patients who fail all other available treatments.
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Introduction

To date, the hospital mortality rate for patients
with coronavirus disease 2019 (COVID-19)
infection requiring mechanical ventilation has
been shown to be greater than 30%.1 The most
frequent cause of death is progressive acute
respiratory disease syndrome (ARDS), which
has failed to respond to available drug treatments or measures to optimize mechanical
ventilation, including paralysis, proning and
novel modes of ventilation. Extra corporeal
membrane oxygenation (ECMO) has been used
as a rescue therapy for these patients in academic and quaternary care centers. Physiologic
advantages of ECMO includes the treatment
of right ventricular dysfunction. Even with the
enhanced availability of resources at these
referral centers, reports of ECMO treatment
outcomes for COVID-19 patients demonstrate
mortality rates of greater than 50%, leading
some researchers to be against recommending
this treatment.2 Our case series evaluates the
clinical outcomes from a community hospital
of a cohort of COVID-19 patients who received
veno-venous (VV) ECMO treatment for refractory ARDS.

Material and Methods

Permission to review electronic medical records retrospectively of all COVID-19 patients
admitted to our intensive care unit (ICU) for
the study period was obtained from our institutional review committee. Between March 1st
and May 31st, 2020, all consecutive COVID-19
patients admitted to the ICU at the Regional
Medical Center of San Jose were evaluated
and included in our electronic database. The
Regional Medical Center of San Jose is a 258bed community hospital with an average daily
census of 170 patients.
The ECMO program is comprised of 2 cardiothoracic surgeons, 14 medical intensivists,
4 perfusionists and 18 ECMO-trained ICU
nurses. There is also a 1:1 patient-nurse ratio,
which augments care to the COVID-19 patients
receiving ECMO. The intensivists and perfusionists remained in-hospital at all times. The
decision to initiate VV ECMO was based on
a consensus between the thoracic surgeon,
attending intensivist and ICU medical director
along with consent from the patient’s family.
Criteria for initiation of VV ECMO included
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clinical evidence of progressive ARDS and
failure of efforts at optimal mechanical ventilation, including proning as well as a ratio of
Pao2/Fio2 (P:F) less than 80 for greater than 6
hours, with Fio2 greater than 80% and positive
end expiratory pressure (PEEP) greater than 10
mm Hg. Patients who were going to receive VV
ECMO were cannulated at their bedsides with
ultrasound guidance and anesthesiology support. During cannulation and at all other times
during the ICU course for COVID-19 patients
receiving mechanical ventilation or ECMO, all
bedside personnel wore enhanced personal
protective equipment (PPE) including positive
airway pressure respirators (PAPR). The procedure rooms were either negative pressure
rooms or standard enclosed normal pressure
ICU rooms with a portable high efficiency
particulate air (HEPA) filter. The patients were
sedated and paralyzed pre-procedure. A right
internal jugular approach was used to place a
28-French Crescent (MC3 Cardiopulmonary,
Dexter, MI) dual lumen ECMO catheter with
distal tip positioned in the inferior vena cava
(IVC). A CentrimagTM (Abbott Laboratories,
Abbott Park, IL) circulatory support system
was used. All patients received continuous
intravenous (IV) heparin adjusted to a partial
thromboplastin time (aPTT) of 1.5 to 2 times
control value. Pre- and post-membrane oxygenation was monitored daily. Lung protective
ventilation strategy was followed per best
practice guidance protocols.3 An infectious
disease consultant guided any indicated anti-bacterial or anti-viral treatment. VV ECMO
was discontinued and patients were decannulated at their bedsides once ventilator support
settings were acceptable per published guidelines.4

Results

During the 3 month study period, 70 patients
with COVID-19 were admitted to the ICU at
Regional Medical Center of San Jose. From
this cohort, 57 (81%) developed acute respiratory failure requiring mechanical ventilation.
Seven (12%) of the mechanically ventilated
patients developed progressive ARDS and met
criteria for initiation of ECMO as described in
the methods section. All patients receiving VV
ECMO were younger than 70 years of age with
a median age of 57 years. Four of the 7 patients
were women and 3 were men. The ethnicities
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of the patients were either Hispanic or Southeast Asian. The median body mass index (BMI)
was 36 kg/m2 and 2 of the 7 patients met the
criteria for morbid obesity with a BMI greater
than 40 kg/m2. Six of the 7 patients were diabetic. Other co-morbidities included 4 patients
with hypertension and 1 with non-ischemic
cardiomyopathy. Three of the 7 patients had
developed bacterial pneumonia, 2 with Klebsiella and 1 with Serratia. Pneumonias were treated with appropriate antibiotics. Two of the 7
patients received remdesevir, tocilizumab and
steroids.
The median duration of VV ECMO was 11 days
with a minimum of 6 days and a maximum of
37 days. The median duration of mechanical
ventilation pre-ECMO was 5 days and 8 days
post-ECMO. Three of the 7 patients received
tracheostomy post-ECMO. The median duration of hospitalization was 40 days. Five of the
7 (71%) VV ECMO patients survived to discharge. Two of the 7 patients were discharged
home, 2 to long-term ambulatory care (LTAC)
facilities and 1 transferred to another hospital
due to a third party payer request. Two patients died, 1 during ECMO cannulation with
perforation of the right ventricle. Another
patient died after 6 days of VV ECMO following
cardiopulmonary arrest that resulted in severe
cerebral anoxia. For the mechanically ventilated patients in our ICU who did not receive VV
ECMO, 34 of 50 patients (68%) survived to
discharge.

Discussion

Discovery of more effective treatments and a
vaccine against COVID-19 infection is being aggressively pursued. Currently, 3–5% of patients
infected with COVID-19 become critically ill.1 In
our hospital, the majority of those admitted
to the ICU developed progressive ARDS and
required mechanical ventilation. The mortality
rate for mechanically ventilated COVID-19 patients, excluding those who received VV ECMO
at our hospital, was 32%, which was similar to
that recently described from a larger cohort.1
The mounting death toll for patients who
fail mechanical ventilation from ARDS due to
COVID-19 makes efforts to salvage their lives
imperative. Our case-series demonstrates
that this life-saving therapy may be available
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to COVID-19 patients at non-academic and
smaller hospitals with ECMO programs. As
was demonstrated with the H1N1 epidemic,5
it is possible to transport ARDS patients to
academic and quaternary care centers for VV
ECMO, though the feasibility of transfer during
the current pandemic may be less likely due to
the scarcity of resources during surge periods.
The availability of on-site ECMO cannulation
and transport teams may also be markedly
limited.
Even with the enhanced availability of resources at these referral centers, reports of ECMO
treatment outcomes for COVID-19 patients
demonstrate mortality rates of greater than
50%, leading some researchers to recommend
against this treatment.2 While the number
of ECMO patients in this case-series is small,
we believe that a well-organized ECMO program in a community hospital with appropriate resources and careful patient selection
can achieve results similar to those of larger
academic centers.6 Our results exceed those
of 2 recently published studies from China of
COVID-19 cohorts comprised of 8 patients7
and 21 patients8 treated with VV ECMO, which
demonstrated survival rates of 50% and 56%
respectively. Additionally, the Extracorporeal
Life Support Organization (ELSO) registry of
COVID-19 patients, receiving predominantly VV
ECMO, indicates a 56% rate of survival to discharge. Another recently published case series
of 40 COVID patients in an academic medical
center demonstrated a survival to discharge of
73%,9 which is similar to the survival rate of our
case series. Compared to the higher mortality
rates of other studies of VV ECMO in diseases
other than COVID, it is possible that increased
survival could be a result of these COVID
patients having few co-morbidities other than
obesity, diabetes mellitus or hypertension.

Conclusion

Our case series suggests that the availability
and efficacy of VV ECMO as a rescue therapy
for patients with progressive ARDS can be
enhanced by the development of ECMO capability at smaller, non-academic hospitals with
appropriate resources, staff training and careful patient selection.
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